Recombinant human VEGF165b protein is an effective anti-cancer agent in mice

被引:84
|
作者
Rennel, Emma S. [1 ]
Hamdollah-Zadeh, Maryam A. [1 ]
Wheatley, Edward R. [2 ]
Magnussen, Anette [1 ]
Schueler, Yvonne [1 ]
Kelly, Sara P. [3 ]
Finucane, Ciara [4 ]
Ellison, David [4 ]
Cebe-Suarez, Stephanie [5 ]
Ballmer-Hofer, Kurt [5 ]
Mather, Stephen [4 ]
Stewart, Lorna [2 ]
Bates, David O. [1 ]
Harper, Steven J. [1 ]
机构
[1] Univ Bristol, Sch Vet Sci, Dept Physiol & Pharmacol, Microvasc Res Labs, Bristol BS2 8EJ, Avon, England
[2] Canc Res Technol, London, England
[3] Univ Walk, Sch Med, Dept Physiol & Pharmacol, Bristol BS8 1TD, Avon, England
[4] Barts & London Queen Marys Sch Med & Dent, Nucl Med Res Lab, London, England
[5] Paul Scherrer Inst, Lab Biomol Res, CH-5232 Villigen, Switzerland
关键词
VEGF; VEGF(165)b; anti-angiogenesis; cancer inhibition; pharmacokinetics; liver toxicity;
D O I
10.1016/j.ejca.2008.05.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumour growth is dependent on angiogenesis, the key mediator of which is vascular endothelial growth factor-A (VEGF-A). VEGF-A exists as two families of alternatively spliced isoforms - pro-angiogenic VEGF(xxx) generated by proximal, and anti-angiogenic VEGF(xxx)b by distal splicing of exon 8. VEGF(165)b inhibits angiogenesis and is downregulated in tumours. Here, we show for the first time that administration of recombinant human VEGF(165)b inhibits colon carcinoma tumour growth and tumour vessel density in nude mice, with a terminal plasma half-life of 6.2 h and directly inhibited angiogenic parameters (endothelial sprouting, orientation and structure formation) in vitro. Intravenous injection of I-125-VEGF(165)b demonstrated significant tumour uptake lasting at least 24 h. No adverse effects on liver function or haemodynamics were observed. These results indicate that injected VEGF(165)b was taken up into the tumour as an effective anti-angiogenic cancer therapy, and provide proof of principle for the development of this anti-angiogenic growth factor splice isoform as a novel cancer therapy. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1883 / 1894
页数:12
相关论文
共 50 条
  • [41] VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease
    Ganta, Vijay Chaitanya
    Choi, Min
    Kutateladze, Anna
    Annex, Brian H.
    CIRCULATION RESEARCH, 2017, 120 (02) : 282 - +
  • [42] The first-in-class anti-cancer agent ABTL0812 is effective in preclinical models of human endometrial cancer.
    Colas, Eva Colas
    Eritja, Nuria
    Munoz-Guardiola, Pau
    Sole-Sanchez, Sonia
    Moiola, Cristian
    Felip, Isidre
    Gil-Moreno, Antonio
    Perez-Montoyo, Hector
    Alfon, Jose Alberto
    Domenech, Caries
    Lizcano, Jose M.
    Matias-Guiu, Xavier
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop
    Boudria, Asma
    Abou Faycal, Cherine
    Jia, Tao
    Gout, Stephanie
    Keramidas, Michelle
    Didier, Chloe
    Lemaitre, Nicolas
    Manet, Sandra
    Coll, Jean-Luc
    Toffart, Anne-Claire
    Moro-Sibilot, Denis
    Albiges-Rizo, Corinne
    Josserand, Veronique
    Faurobert, Eva
    Brambilla, Christian
    Brambilla, Elisabeth
    Gazzeri, Sylvie
    Eymin, Beatrice
    ONCOGENE, 2019, 38 (07) : 1050 - 1066
  • [44] Combination of Chlorambucil and Mercaptopurine Show Effective Anti-Cancer Effects in Mice Model
    Xu, Weibing
    Di, Yuxin
    Chu, Shengjing
    Wang, Zixuan
    Long, Haitao
    Pu, Lumei
    Ma, Runtian
    Wang, Yanwei
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2023, 18 : 8131 - 8141
  • [45] VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop
    Asma Boudria
    Cherine Abou Faycal
    Tao Jia
    Stephanie Gout
    Michelle Keramidas
    Chloé Didier
    Nicolas Lemaître
    Sandra Manet
    Jean-Luc Coll
    Anne-Claire Toffart
    Denis Moro-Sibilot
    Corinne Albiges-Rizo
    Véronique Josserand
    Eva Faurobert
    Christian Brambilla
    Elisabeth Brambilla
    Sylvie Gazzeri
    Beatrice Eymin
    Oncogene, 2019, 38 : 1050 - 1066
  • [46] WT1TMT396/+ MICE WITH MURINE DENYS-DRASH SYNDROME HAVE REDUCED VEGF165B PROTEIN WITH ADVANCING DISEASE BUT NORMAL LEVELS PRIOR TO THE ONSET OF DISEASE
    Wroe, C.
    White, K. E.
    Woolard, J.
    Miles, C. G.
    PEDIATRIC NEPHROLOGY, 2009, 24 (09) : 1791 - 1791
  • [47] Recombinant GnRH-p53 fusion protein greatly enhances the anti-cancer efficacy of DNA-damaging agent fluorouracil in human breast cancer xenograft tumors
    Chen, Li
    Yan, Zhenwen
    Lin, Xinli
    Li, Lu-Yuan
    CANCER RESEARCH, 2009, 69
  • [48] Correction to: VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop
    Asma Boudria
    Cherine Abou Faycal
    Tao Jia
    Stephanie Gout
    Michelle Keramidas
    Chloé Didier
    Nicolas Lemaître
    Sandra Manet
    Jean-Luc Coll
    Anne-Claire Toffart
    Denis Moro-Sibilot
    Corinne Albiges-Rizo
    Véronique Josserand
    Eva Faurobert
    Christian Brambilla
    Elisabeth Brambilla
    Sylvie Gazzeri
    Beatrice Eymin
    Oncogene, 2023, 42 : 2471 - 2472
  • [49] POST-ISCHEMIC EXPRESSION OF AN ANTI-ANGIOGENIC FACTOR VEGF165B AND ITS INHIBITORY EFFECT ON POST-ISCHEMIC ANGIOGENESIS IN RATS.
    Ishikawa, M.
    Takahashi, T.
    Kanazawa, M.
    Kawamura, K.
    Toriyabe, M.
    Miura, M.
    Koyama, M.
    Nishizawa, M.
    Shimohata, T.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2016, 36 : 218 - 219
  • [50] PRODUCTION OF HUMAN-LEUKOCYTE INTERFERON FOR USE AS AN ANTI-VIRAL AND ANTI-CANCER AGENT
    SCHOUB, BD
    BAKER, E
    ORCHARD, ME
    MCMENAMIN, SH
    SOUTH AFRICAN JOURNAL OF SCIENCE, 1980, 76 (06) : 258 - 260